Progress and prospect in the clinical translation of cancer nanomedicine
10.16438/j.0513-4870.2021-1259
- VernacularTitle:抗肿瘤纳米药物的临床转化进展及展望
- Author:
Zhao-hui WANG
;
Yu-ling LIU
- Publication Type:Research Article
- Keywords:
tumor therapy;
nanomedicine;
targeted therapy;
clinical translation;
patient stratification;
biomarker
- From:
Acta Pharmaceutica Sinica
2022;57(1):134-141
- CountryChina
- Language:Chinese
-
Abstract:
Nanotechnology has shown broad application prospects in the diagnosis and treatment of cancer. Currently, nearly 80 cancer nanomedicines are under clinical investigation, and many have been approved with enhanced anti-tumor efficacy and decreased side effects. However, the presence of various barriers in related basic research, process control and clinical trials lead to extremely low translation rate. From the perspective of clinical commercialization, we summarized the progress, clinical status, challenges and opportunities of cancer nanomedicine, and presented a cutting-edge prospect on the rational design of nanomedicine and clinical trial strategies.
